Analysts Anticipate Illumina, Inc. (ILMN) Will Announce Quarterly Sales of $737.73 Million
Wall Street brokerages predict that Illumina, Inc. (NASDAQ:ILMN) will report sales of $737.73 million for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have made estimates for Illumina’s earnings. The lowest sales estimate is $728.41 million and the highest is $749.00 million. Illumina posted sales of $619.35 million in the same quarter last year, which suggests a positive year-over-year growth rate of 19.1%. The business is scheduled to issue its next earnings results on Tuesday, January 30th.
On average, analysts expect that Illumina will report full-year sales of $737.73 million for the current year, with estimates ranging from $2.70 billion to $2.75 billion. For the next fiscal year, analysts expect that the business will post sales of $3.07 billion per share, with estimates ranging from $2.94 billion to $3.19 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Illumina.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.12. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The firm had revenue of $714.00 million for the quarter, compared to analysts’ expectations of $692.77 million. During the same quarter last year, the business earned $0.97 earnings per share. The business’s revenue was up 17.6% on a year-over-year basis.
Illumina (NASDAQ:ILMN) opened at $244.72 on Monday. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41. Illumina has a fifty-two week low of $156.50 and a fifty-two week high of $245.96. The stock has a market cap of $35,730.00, a P/E ratio of 46.17, a PEG ratio of 3.30 and a beta of 0.79.
In other Illumina news, Director Jay T. Flatley sold 20,000 shares of the firm’s stock in a transaction on Tuesday, October 24th. The stock was sold at an average price of $210.43, for a total transaction of $4,208,600.00. Following the completion of the transaction, the director now owns 539,176 shares of the company’s stock, valued at $113,458,805.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Marc Stapley sold 2,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $205.48, for a total value of $410,960.00. Following the transaction, the executive vice president now directly owns 30,370 shares of the company’s stock, valued at approximately $6,240,427.60. The disclosure for this sale can be found here. Insiders have sold 137,671 shares of company stock valued at $29,485,768 in the last three months. Insiders own 0.89% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Illumina by 2.6% in the 2nd quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock worth $1,718,601,000 after purchasing an additional 255,498 shares during the last quarter. Ameriprise Financial Inc. raised its position in shares of Illumina by 3.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 2,512,167 shares of the life sciences company’s stock worth $500,416,000 after purchasing an additional 76,452 shares during the last quarter. Capital World Investors raised its position in shares of Illumina by 23.8% in the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after purchasing an additional 410,000 shares during the last quarter. Winslow Capital Management LLC purchased a new position in shares of Illumina in the 2nd quarter worth about $211,584,000. Finally, Legal & General Group Plc raised its position in shares of Illumina by 2.6% in the 3rd quarter. Legal & General Group Plc now owns 684,955 shares of the life sciences company’s stock worth $136,442,000 after purchasing an additional 17,081 shares during the last quarter. 91.60% of the stock is owned by hedge funds and other institutional investors.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.